1.960USDMkt Cap: 676.50M USDP/E: —Last update: 2026-05-21
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipe…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap676.50M USD
Enterprise Value490.67M USD
Revenue (TTM)—
Gross Profit-131.96M USD
Net Income (TTM)-190.89M USD
Revenue/Share—
Last Price1.960 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees150
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.55
PEG—
EV/EBITDA-2.79
EV/Revenue—
P/S—
P/B1.72
EPS (TTM)-0.77
EPS (Forward)-0.77
52W Range
1.84096% of range1.965
52W High1.965 USD
52W Low1.840 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.25%
ROA-45.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-149.25M USD
CapEx (TTM)386.00K USD
FCF Margin—
FCF Yield-10.34%
Net Debt-185.84M USD
Net Debt/EBITDA1.06
Balance Sheet
Debt/Equity0.28
Current Ratio9.65
Quick Ratio9.47
Book Value/Sh1.139 USD
Cash/Share0.7730 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.350 USD
Target Range3.850 USD – 14.00 USD
# Analysts11
Ownership
Shares Out.345.15M
Float269.64M
Insiders11.05%
Institutions52.91%
Short Interest
Short Ratio2.4d
Short % Float11.82%
Short % Out.10.68%
Shares Short36.86M
Short (prev mo.)32.06M
Technical
SMA 502.317 (-15.4%)
SMA 2001.672 (+17.2%)
Beta0.46
S&P 52W Chg28.31%
Avg Vol (30d)4.33M
Avg Vol (10d)6.54M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—